My Companies
Notification
Account
Log Out
Login
Wholly owned subsidiary Bacil Research and Development entered agreement with Efdee Pharma for research and development of pharmaceutical products including pellets, granules, powders, tablets and capsules at estimated cost of Rs 35 crore.
Bacil Pharma Board Approves ₹50 Crore Rights Issue to Existing Shareholders
Niraj Shah Acquires 6.44% Stake in Bacil Pharma via Open Market
Bacil Pharma Board Approves ₹50 Crore Fundraising via Equity Instruments
Bacil Pharma Non-Promoter Manubhai Shah Sells 2.75% Stake in Two Days
Bacil Pharma Non-Promoter Nikita Patel Sells 7.10% Stake in Two Days